Long-term safety of HSK44459 in IPF patients
Treatments studied
Part of Lungs & breathing clinical trials.
This trial checks the long-term safety of HSK44459 for people with IPF who have already taken it in a previous study. It is only for those who finished the prior treatment without major issues and may benefit from continuing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the last dose of HSK44459 in a previous trial without stopping early.
- You must not be planning to have a lung transplant.
- You must not have lost more than 10% of your body weight during the previous study.
- You must not have had cancer in the last 5 years.
- You must not have a history of depression or anxiety disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, HSK50042, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help slow lung function decline, and is looking for patients who meet specific lung function criteria and are either not currently on anti-fibrotic therapy or on a stable dose.
This is an early-stage safety and tolerability study of a new drug called HW241045 in healthy volunteers. Researchers will test the drug at different doses to understand how the body processes it and what side effects it may cause.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
This study tests a new medication called AK3280 for people with idiopathic pulmonary fibrosis (IPF), a lung condition. The goal is to see if AK3280 can help improve lung function. To join, you must have a confirmed IPF diagnosis and meet certain health criteria.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.